Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen

[1]  A. Scott,et al.  HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan , 2006, Clinical Cancer Research.

[2]  J. Valcárcel,et al.  Intron Removal Requires Proofreading of U2AF/3' Splice Site Recognition by DEK , 2006, Science.

[3]  K. Münger,et al.  The Human DEK Proto-Oncogene Is a Senescence Inhibitor and an Upregulated Target of High-Risk Human Papillomavirus E7 , 2005, Journal of Virology.

[4]  Stephanie Schneider,et al.  Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma , 2005, Oncogene.

[5]  Bryon D Johnson,et al.  Neuroblastoma Cells Transiently Transfected to Simultaneously Express the Co-Stimulatory Molecules CD54, CD80, CD86, and CD137L Generate Antitumor Immunity in Mice , 2005, Journal of immunotherapy.

[6]  T. Leblanc,et al.  DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification , 2005, Leukemia.

[7]  L. Old,et al.  CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. , 2005, Blood.

[8]  M. Brenner,et al.  Vaccine therapies for pediatric malignancies. , 2005, Cancer journal.

[9]  L. Old,et al.  Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Schulz,et al.  Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer , 2005, Molecular Cancer.

[11]  R. Knippers,et al.  The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin. , 2004, Gene.

[12]  Qing-Rong Chen,et al.  Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma , 2004, Cancer Research.

[13]  I. Scholten,et al.  Functional Domains of the Ubiquitous Chromatin Protein DEK , 2004, Molecular and Cellular Biology.

[14]  M. Przybylski,et al.  Phosphorylation by Protein Kinase CK2 Changes the DNA Binding Properties of the Human Chromatin Protein DEK , 2004, Molecular and Cellular Biology.

[15]  William W. Kwok,et al.  Autoreactive T Cells in Healthy Individuals1 , 2004, The Journal of Immunology.

[16]  J. Ritz,et al.  Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation , 2004, The Journal of experimental medicine.

[17]  Sakari Knuutila,et al.  Clustering of molecular alterations in gastroesophageal carcinomas. , 2004, Neoplasia.

[18]  A. Huvos,et al.  Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.

[19]  H. Ikeda,et al.  CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Bryon D Johnson,et al.  Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. , 2003, Cellular immunology.

[21]  A. Davidoff,et al.  Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. , 2003, Blood.

[22]  M. Tanimoto,et al.  Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes , 2002, Leukemia.

[23]  M. Fujimuro,et al.  Protein Interactions Targeting the Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus to Cell Chromosomes , 2002, Journal of Virology.

[24]  T. Elliott,et al.  Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens , 2002, European journal of immunology.

[25]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[26]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[27]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[28]  M. Pfreundschuh,et al.  Serological identification of human tumor antigens. , 1997, Current opinion in immunology.

[29]  D. Markovitz,et al.  DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Kwok,et al.  Human Class II Major Histocompatibility Complex Gene Transfer into Murine Neuroblastoma Leads to Loss of Tumorigenicity, Immunity Against Subsequent Tumor Challenge, and Elimination of Microscopic Preestablished Tumors , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[32]  A. A. Brian,et al.  Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing , 1994, Cancer Immunology, Immunotherapy.

[33]  R. McIvor,et al.  Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[34]  M. Meyn,et al.  Expression cloning of multiple human cDNAs that complement the phenotypic defects of ataxia-telangiectasia group D fibroblasts. , 1993, American journal of human genetics.

[35]  M. Fornerod,et al.  The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA , 1992, Molecular and cellular biology.

[36]  A. Evans,et al.  The significance of primitive cells in marrow aspirates of children with neuroblastoma , 1973, Cancer.

[37]  Bill Ah.  The implications of immune reactions to neuroblastoma. , 1969 .

[38]  I. Hellstrom,et al.  Demonstration of cell-bound and humoral immunity against neuroblastoma cells. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Ritz,et al.  Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. , 2004, Blood.

[40]  Mattias Höglund,et al.  Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution , 2004, International journal of cancer.

[41]  M. Akizuki,et al.  Autoantibodies to DEK oncoprotein in human inflammatory disease. , 2000, Arthritis and rheumatism.

[42]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[43]  A. H. Bill.  The implications of immune reactions to neuroblastoma. , 1969, Surgery.